JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300

Benzinga · 4d ago
JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $276 to $300.